本研究旨在分析18F标记成纤维细胞激活蛋白抑制剂(18F-FAPI)在胰腺的非特异性摄取(NSU)特性,并探讨其相关因素。完全正确,78例同时接受18F-脱氧葡萄糖(FDG)和18F-FAPIPET/CT检查的患者分为正常(n=53)和NSU(n=25)组。一般信息的差异,病史,比较了实验室指标和摄取量。接收器工作特征(ROC)曲线用于分析最佳截止值。18F-FAPI-SUVmax与血细胞分析的相关性,肝功能指标,肿瘤标志物,并对炎症指标进行分析。采用logistic回归模型估计独立因素。两者18F-FAPI(4.48±0.98vs.2.01±0.53,t=11.718,P<0.05)和18F-FDG(2.23±0.42vs.2.02±0.44,t=2.036,P=0.045)显示NSU组明显高于NSU组。NSU组患者有饮酒史(P=0.034),慢性肝病(P=0.006),和胃切除术(P=0.004)。ROC分析显示18F-FAPI和18F-FDG在鉴定NSU时的截断值为3.25和2.05。NSU组患者的血小板计数较少,血小板体积增大,总胆红素较高,直接或间接胆红素(P<0.05)。血小板计数,血小板crit,大血小板比率,天冬氨酸转氨酶(AST),α-L-岩藻糖苷酶,总,直接或间接胆红素与18F-FAPI-SUVmax相关(P<0.05)。AST[1.099(1.014,1.192),P=0.021]和总胆红素[1.137(1.035,1.249),P=0.007]是逐步Logistic回归的两个独立因素,和血小板/%[1.079(1.004,1.160),P=0.039]和总胆红素[1.459(1.016,2.095),P=0.041]是预测18F-FAPI胰腺摄取的反向逻辑回归的两个独立因素。18F-FAPI-PET/CT在预测胰腺NSU方面优于18F-FDG,NSU与饮酒史有关,慢性肝病,胃切除术,异形血小板,肝功能受损.
This
study aimed to analyze the characteristics of the non-specific uptake (NSU) of 18F-labeled fibroblast activation protein inhibitor (18F-FAPI) of the pancreas and investigate the related factors. Totally, 78 patients who underwent both 18F-fluorodeoxyglucose (FDG) and 18F-FAPI PET/CT examinations were divided into normal (n = 53) and NSU (n = 25) groups. The differences in general information, medical history, laboratory indexes and uptake were compared. Receiver operating characteristic (ROC) curves were used to analyze the optimal cut-off values. The correlations between 18F-FAPI-SUVmax and blood cell analysis, liver function indexes, tumor markers, and inflammatory indices were analyzed. The logistic regression model was used to estimate the independent factors. Both 18F-FAPI (4.48 ± 0.98 vs. 2.01 ± 0.53, t = 11.718, P < 0.05) and 18F-FDG (2.23 ± 0.42 vs. 2.02 ± 0.44, t = 2.036, P = 0.045) showed significantly higher in NSU group. Patients in the NSU group tended to be complicated with a history of drinking (P = 0.034), chronic liver diseases (P = 0.006), and surgery of gastrectomy (P = 0.004). ROC analysis showed cutoff values of 3.25 and 2.05 for 18F-FAPI and 18F-FDG in identifying the NSU. Patients in the NSU group showed less platelet count, higher platelet volume, higher total bilirubin, direct or indirect bilirubin (P < 0.05). Platelet count, platelet crit, large platelet ratio, aspartate aminotransferase (AST), α-L-fucosidase, and total, direct or indirect bilirubin were correlated with 18F-FAPI-SUVmax (P < 0.05). AST [1.099 (1.014, 1.192), P = 0.021] and total bilirubin [1.137 (1.035, 1.249), P = 0.007] were two independent factors in the step forward logistic regression, and platelet/% [1.079 (1.004, 1.160), P = 0.039] and total bilirubin [1.459 (1.016, 2.095), P = 0.041] were two independent factors in the step backward logistic regression for the prediction of pancreatic uptake of 18F-FAPI. 18F-FAPI-PET/CT was better than 18F-FDG in predicting the pancreatic NSU, and NSU is related to a history of drinking, chronic liver diseases, gastrectomy, heteromorphic platelet, and impaired liver function.